CND’s Syn-One Test Shows 75% Detection in Sleep Disorder
CND Life Sciences reported baseline results from its NIH-sponsored Syn-Sleep Study, demonstrating the Syn-One Test’s ability to detect phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder (iRBD). The 24-month longitudinal study enrolled 80 participants across 11 US sites, representing a critical validation step for cutaneous biomarker detection in prodromal neurodegenerative … Read more